By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Explainer-What you need to know about RSV and the new vaccines
Stocks

Explainer-What you need to know about RSV and the new vaccines

News Room
Last updated: 2023/09/23 at 4:57 AM
By News Room
Share
6 Min Read
SHARE
2/2

© Reuters. FILE PHOTO: A company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

2/2

By Michael Erman

(Reuters) -The U.S. Centers for Disease Control and Prevention (CDC) on Friday recommended Pfizer (NYSE:)’s respiratory syncytial virus (RSV) vaccine for women in the middle of the third trimester of pregnancy to protect their babies from severe illness.

That Pfizer shot and one developed by GSK in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness. In August, Pfizer’s vaccine also won approval for the maternal use. Here’s what you need to know.

What is RSV?

RSV is a usually seasonal respiratory virus that generally causes mild, cold-like symptoms. Still, infants and older adults have a higher risk of developing severe RSV.

RSV leads to 58,000 to 80,000 hospitalizations among children under age 5, and 60,000 to 160,000 hospitalizations among adults age 65 and older each year, according to the CDC. It causes around 14,000 deaths in adults aged 65 and older in the U.S. annually, according to government estimates.

Who should get the vaccines?

The U.S. CDC has recommended that adults aged 60 or older may get the shot after discussions with a healthcare provider about whether RSV vaccination is right for them. The agency stopped short of saying all adults over the age of 60 should receive it this year.

Outside advisers to the CDC suggested the narrower recommendation in June after expressing concern that there was not sufficient data on how effective the vaccines are in people over age 75 and in other high-risk groups.

CDC Director Dr. Mandy Cohen formally recommended use of the vaccine in expecting mothers to protect infants up to age 6 months after the agency’s Advisory Committee on Immunization Practices voted 11-1 in its favor. The panel recommended use of the shot in women 32 weeks to 36 weeks into their pregnancy from September to January, in order to protect babies born in peak RSV season.

How often do I need to get the vaccine to stay protected?

Early data suggests that the RSV shots are protective for at least two years, but it is not yet clear how often older adults will need to be revaccinated. CDC advisers will consider the frequency of revaccination when more data becomes available.

What else is available to protect infants from RSV?

In July, the FDA also approved Beyfortus, a long-acting antibody therapy from Sanofi (NASDAQ:) and partner AstraZeneca (NASDAQ:), to prevent RSV in children up to 24 months of age.

Previously, Swedish Orphan Biovitrum’s Synagis was the only approved preventive therapy in the U.S. for high-risk infants. Synagis is given as monthly injections, while Beyfortus can be given annually.

Are RSV cases on the rise?

Yes, although not alarmingly so. Detection of the virus in testing has increased significantly over the last month to around the same levels as this spring, according to CDC data. Still, that is a fraction of the positive tests recorded at the same time a year ago, when RSV cases were surging around the country and hospitals were running out of pediatric beds.

Can I get the RSV shot alongside my COVID and flu shots?

Yes, current CDC guidelines allow for all three vaccines to be administered simultaneously, even though they have not been tested together.

“If it’s now or never again, it’s best to get all the vaccines you’re eligible for to get the protection against as many diseases as possible,” said Dr. Jeffrey Duchin, a member of the board of directors for the Infectious Diseases Society of America. “If you’ve got the luxury of returning for more than one visit, you can choose to space them out.”

Will my insurance cover it?

Adults who are insured under the U.S. Medicare program for people aged 65 and older or disabled are covered for the vaccine. Many private insurance plans, including large insurers like CVS Health (NYSE:)’s Aetna, Humana (NYSE:) and Elevance, which owns Blue Cross Blue Shield insurers including Anthem, also say they are covering the shot for adults 60 and older who are not yet eligible for Medicare. Typically you do not need a prescription.

Keep up with the latest medical breakthroughs and healthcare trends with our newsletter Reuters Health Rounds. Sign up here.

Read the full article here

News Room September 23, 2023 September 23, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Beyond Meat: Why this strategist has ‘no interest’ in this meme stock

Watch full video on YouTube

‘Ghost jobs’ are adding another layer of uncertainty to the stalling jobs picture

Watch full video on YouTube

Harbor Dividend Growth Leaders ETF Q3 2025 Commentary (GDIV)

Harbor Capital is an asset manager focused on curating an intentionally select…

Digital bank N26 appoints UBS executive as new chief after fresh sanctions

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Gold’s decline could be the start of a correction. 📉

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?